Predictors of premature antidepressant discontinuation in functional gastrointestinal disorders

Psychosomatic Medicine

Volumn 69, Issue 2, 2007, Pages 173-181

  Sayuk, Gregory S ^a   Elwing, Jill E ^a   Lustman, Patrick J ^a,b   Clouse, Ray E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Depression; Functional gastrointestinal disorders; Somatization

Indexed keywords

ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE DISTRIBUTION; ANXIETY DISORDER; CONTROLLED STUDY; DEPRESSION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTPATIENT; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEX RATIO; SOMATIZATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; AGE; ARTICLE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOMATOFORM DISORDER;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SEX FACTORS; SOMATOFORM DISORDERS;

EID: 33847760695     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/PSY.0b013e318031391d     Document Type: Review

References (71)

1. Clouse RE. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 1994;39:2352-63.
2. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136-46.
3. Whitehead WE, Levy RL, Von Korff M, Feld AD, Palsson OS, Turner M, Drossman DA. The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1305-15.
4. Talley NJ. Antidepressants in IBS: are we deluding ourselves? Am J Gastroenterol 2004;99:921-3.
5. Lembo A. Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol 2004;38:776-81.
6. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31.
7. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-16.
8. Clouse RE. Antidepressants for irritable bowel syndrome. Gut 2003;52:598-9.
9. Thiwan SM, Dalton CB, Morris CB, Diamant NE, Toner BB, Whitehead WE, Hu Y, Bangdiwala SI, Drossman D. Factors predicting symptoms of "side effects" when using tricyclic antidepressants. Gastroenterology 2005;128:A66.
10. Lancaster-Smith MJ, Prout BJ, Pinto T, Anderson JA, Schiff AA. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 1982;66:33-41.
11. Drossman D TN, Thompson W, Whitehead W, Corazzari E, eds. Rome II: functional gastrointestinal disorders. McLean, VA: Degnon Assoc., Inc.; 2000.
12. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-56.
13. Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993;34:229-34.
14. Assoc AP. Diagnostic and statistical manual of mental disorders. Washington, DC: APA; 1994.
15. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258-66.
16. Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999;44:2373-9.
17. Prakash C, Lustman PJ, Freedland KE, Clouse RE. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci 1998;43:1951-6.
18. Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2006 Dec 30; Epub ahead of print.
19. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253-69.
20. Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005;54:1332-41.
21. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
22. Clouse RE, Prakash C, Anderson RJ. Antidepressants for functional gastrointestinal symptoms and syndromes: a meta-analysis. Gastroenterology 2001;120:A642.
23. Woodman CL, Breen K, Noyes R Jr, Moss C, Fagerholm R, Yagla SJ, Summers R. The relationship between irritable bowel syndrome and psychiatric illness. A family study. Psychosomatics 1998;39:45-54.
24. Walker EA, Gelfand AN, Gelfand MD, Katon WJ. Psychiatric diagnoses, sexual and physical victimization, and disability in patients with irritable bowel syndrome or inflammatory bowel disease. Psychol Med 1995;25:1259-67.
25. Walker EA, Roy-Byrne PP, Katon WJ, Li L, Amos D, Jiranek G. Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psychiatry 1990;147:1656-61.
26. Clouse RE. Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial. Gastroenterology 2003;125:249-53.
27. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(Suppl 22):30-3.
28. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. Jama 2002;288:1403-9.
29. Al-Chaer E, Kawasaki M, Paricha P. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000;119:1276-85.
30. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-72.
31. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994;8:48-53.
32. Kobak KA, Taylor L, Katzelnick DJ, Olson N, Clagnaz P, Henk HJ. Antidepressant medication management and health plan employer data information set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry 2002;63:727-32.
33. Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms in treatment-resistant depression. Psychiatry Res 2003;118:39-45.
34. Agosti V, Quitkin FM, Stewart JW, McGrath PJ. Somatization as a predictor of medication discontinuation due to adverse events. Int Clin Psychopharmacol 2002;17:311-4.
35. Keeley R, Smith M, Miller J. Somatoform symptoms and treatment nonadherence in depressed family medicine outpatients. Arch Fam Med 2000;9:46-54.
36. North CS, Downs D, Clouse RE, Alrakawi A, Dokucu ME, Cox J, Spitznagel EL, Alpers DH. The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol 2004;2:787-95.
37. Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH. The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25-30.
38. Brown WH, Chey WD, Elta GH. Number of responses on a review of systems questionnaire predicts the diagnosis of functional gastrointestinal disorders. J Clin Gastroenterol 2003;36:222-7.
39. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400-6.
40. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998;115:1263-71.
41. Vandvik PO, Wilhelmsen I, Ihlebaek C, Farup PG. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther 2004;20:1195-203.
42. Smith RC, Gardiner JC, Lyles JS, Sirbu C, Dwamena FC, Hodges A, Collins C, Lein C, Given CW, Given B, Goddeeris J. Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. Psychosom Med 2005;67:123-9.
43. Blanchard EB, Keefer L, Galovski TE, Taylor AE, Turner SM. Gender differences in psychological distress among patients with irritable bowel syndrome. J Psychosom Res 2001;50:271-5.
44. Lee OY, Mayer EA, Schmulson M, Chang L, Naliboff B. Gender-related differences in IBS symptoms. Am J Gastroenterol 2001;96:2184-93.
45. Munakata J, Naliboff B, Harraf F, Kodner A, Lembo T, Chang L, Silverman DH, Mayer EA. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997;112:55-63.
46. Naliboff BD, Berman S, Chang L, Derbyshire SW, Suyenobu B, Vogt BA, Mandelkern M, Mayer EA. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003;124:1738-47.
47. Berman S, Munakata J, Naliboff BD, Chang L, Mandelkern M, Silverman D, Kovalik E, Mayer EA. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain 2000;4:157-72.
48. Tillisch K, Mayer EA, Labus JS, Stains J, Chang L, Naliboff BD. Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 2005;54:1396-401.
49. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59.
50. Brown FW, Golding JM, Smith GR Jr. Psychiatric comorbidity in primary care somatization disorder. Psychosom Med 1990;52:445-51.
51. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-35.
52. Kroenke K, Spitzer RL, Williams JB, Linzer M, Hahn SR, deGruy FV, 3rd, Brody D. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-9.
53. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. Am J Med 1997;103:339-47.
54. Kroenke K, Rosmalen JG. Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. Med Clin North Am 2006;90:603-26.
55. Katon W, Lin E, Von Korff M, Russo J, Lipscomb P, Bush T. Somatization: a spectrum of severity. Am J Psychiatry 1991;148:34-40.
56. Katon W, Kleinman A, Rosen G. Depression and somatization: a review. Part I. Am J Med 1982;72:127-35.
57. Bridges KW, Goldberg DP. Somatic presentation of DSM III psychiatric disorders in primary care. J Psychosom Res 1985;29:563-9.
58. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-41.
59. Sawhney M, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for persistent or recurrent vomiting in diabetic patients. Gastroenterology 2001;120:A243.
60. Seltzer A, Roncari I, Garfinkel P. Effect of patient education on medication compliance. Can J Psychiatry 1980;25:638-45.
61. Lin EH, Von Korff M, Ludman EJ, Rutter C, Bush TM, Simon GE, Unutzer J, Walker E, Katon WJ. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry 2003;25:303-10.
62. Hoffman L, Enders J, Luo J, Segal R, Pippins J, Kimberlin C. Impact of an antidepressant management program on medication adherence. Am J Manag Care 2003;9:70-80.
63. Peveler R, George C, Kinmonth AL, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ 1999;319:612-5.
64. Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E, Robinson P. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
65. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002;36:578-84.
66. Katon W, Von Korff M, Lin E, Simon G, Walker E, Unutzer J, Bush T, Russo J, Ludman E. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999;56:1109-15.
67. Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 1995;273:1026-31.
68. Paykel ES. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol 2006;1-6.
69. Smith RC, Lyles JS, Gardiner JC, Sirbu C, Hodges A, Collins C, Dwamena FC, Lein C, William Given C, Given B, Goddeeris J. Primary care clinicians treat patients with medically unexplained symptoms: a randomized controlled trial. J Gen Intern Med 2006;21:671-7.
70. Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr Scand 2000;403(Suppl):50-6.
71. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997;170:120-7.